EBA Brunsting-Perry typeL12.30

Last updated on: 18.04.2025

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

EBA with the picture of localized scarring pemphigoid Brunsting-Perry with blisters on the head and neck without mucosal involvement.

ClinicThis section has been translated automatically.

In the inflammatory forms of EBA (see Epidermolysis bullosa acquisita/overview below), skin changes occur all over the skin, not just in the areas most frequently exposed to trauma. Therefore, it may resemble other subepidermal autoimmune bullous dermatoses, such as bullous pemphigoid (BP), mucous membrane pemphigoid (MMP), linear IgA bullous dermatosis and Brunsting-Perry pemphigoid. The occurrence of scars and milia during the course of the disease is rarer than in mechanobullous, classic EBA.

In EBA, scarring pemphigoid-like, the lesions are only on the skin. They are limited to the head, neck and shoulder area. The disease can progress with persistent erosions and atrophic scars (Tanaka, N et al. 2009). It often presents as a chronic and therapy-resistant scarring alopecia with extensive erosions and crusts. Blisters are only rarely registered and then only in an acute flare-up phase. Mucosal infestation is absent (the clinical picture is almost identical to bullous pemphigoid type Brunsting-Perrry).

TherapyThis section has been translated automatically.

Depending on the scarring pemphigoid (glucocorticoids systemically or locally depending on the findings). In addition, diaminodiphenylsulfone (DADPS) is recommended.

Another treatment option is off-label use with dupilumab (Raef HS et al. 2021).

LiteratureThis section has been translated automatically.

  1. Hallel-Halevy D et al (2001) Epidermolysis bullosa acquisita: update and review. Clin Dermatol 19: 712-718.
  2. Hertl M, Schuler G (2002) Bullous autoimmune dermatoses. 1: Classification. Dermatologist 53: 207-219
  3. Kim JH et al (2013) Epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol 27: 1204-1213
  4. Koga H et al (2018) Epidermolysis bullosa acquisita: the 2019 update. Front Med 5 362
  5. Kridin K et al (2019) Epidermolysis bullosa acquisita: A comprehensive review. Autoimmune Rev 18: 786-795
  6. Prost-Squarcioni C et al (2018) International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. Br J Dermatol 179: 30-41
  7. Tanaka, N et al. (2009) A case of epidermolysis bullosa acquisita with clinical features of Brunsting-Perry pemphigoid showing an excellent response to colchicine. J Am Acad Dermatol 61: 715-719
  8. Vodegel RM (2003) Anti-epiligrin cicatricial pemphigoid and epidermolysis bullosa acquisita: differentiation by use of indirect immunofluorescence microscopy. J Am Acad Dermatol 48: 542-547
  9. Woodley DT et al. (1984) Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310: 1007-1013

Last updated on: 18.04.2025